NexoBrid is a topically administered, bromelain-based biological product containing a sterile mixture of proteolytic enzymes. The Food and Drug Administration (FDA) has expanded the approval of ...
(RTTNews) - MediWound Ltd. (MDWD) announced the FDA has completed their filing review and accepted a supplement to the NexoBrid biologics license application for the removal of eschar in pediatric ...
Full commercial launch of NexoBrid marks important first step to becoming the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns NexoBrid ...
Potential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Label supported by robust clinical data demonstrating significantly ...
Credit: Getty Images. NexoBrid is a topically administered, bromelain-based biological product containing a sterile mixture of proteolytic enzymes. The Food and Drug Administration (FDA) has approved ...
CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the recent ...
Please provide your email address to receive an email when new articles are posted on . Phase 3 data shows NexoBrid allows for the early complete eschar removal in more than 90% of patients. This ...
The management of 12 Italian patients with severe burns from a fire on 1 January 2026 at the Crans-Montana ski resort in Switzerland provided a real-world demonstration of emerging strategies for ...
CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results